
First published in the *Government Gazette*, Electronic Edition, on 31 May 2022 at 5 pm.

No. S 445

INFECTIOUS DISEASES ACT 1976

INFECTIOUS DISEASES (COVID-19 ACCESS RESTRICTIONS AND CLEARANCE) (AMENDMENT NO. 10) REGULATIONS 2022

In exercise of the powers conferred by section 73(1) of the Infectious Diseases Act 1976, the Minister for Health makes the following Regulations:

Citation and commencement

1. These Regulations are the Infectious Diseases (COVID-19 Access Restrictions and Clearance) (Amendment No. 10) Regulations 2022 and come into operation on 1 June 2022.

Amendment of regulation 2

2. In regulation 2(1) of the Infectious Diseases (COVID-19 Access Restrictions and Clearance) Regulations 2021 (G.N. No. S 273/2021) (called in these Regulations the principal Regulations) —

(a) in the definition of “cleared status certificate”, replace “or (5)” with “, (5) or (5A)”;

(b) in the definition of “nationwide approved vaccine”, after paragraph (c), insert —

“(d) COVOVAX COVID-19 vaccine or Nuvaxovid (Novavax COVID-19 vaccine);” and

(c) in the definition of “primary vaccination”, replace “regulation 6” with “regulation 6(4)”.

Amendment of regulation 6**3. In regulation 6 of the principal Regulations —**

(a) in paragraph (5), replace sub-paragraphs (a) and (b) with —

“(a) if the recovered individual underwent only a primary vaccination — for the period specified in sub-paragraph (i) or (ii), whichever ends later:

(i) 270 days, starting the date the last dose of the primary vaccination was administered on the recovered individual;

(ii) 180 days, starting the date the recovered individual first tested positive for SARS-CoV-2 upon undergoing any of the following that led to the assessment of the individual having the last infection:

(A) a polymerase chain reaction test;

(B) an antigen rapid test followed by a serology test in Singapore that is not attributable to the administration of any vaccine against a COVID-19 infection;

(C) an antigen rapid test on or after 6 January 2022 that is performed by or under the direction of the individual’s treating doctor in the course of providing medical treatment to the individual because the individual has acute respiratory symptoms;

-
-
- (D) a serology test in Singapore that is not attributable to the administration of any vaccine against a COVID-19 infection and without having tested positive for SARS-CoV-2 on any other occasion;
 - (E) an antigen rapid test in Singapore (whether before, on or after 23 February 2022) that is performed by or under the direction of an approved test provider or is self-administered by the individual under the supervision of an approved test provider;
- (b) if the recovered individual was granted a certificate under paragraph (4) stating that the individual has a cleared status (general) for a period of 120 days — for a period of 270 days starting the date the recovered individual first tested positive for SARS-CoV-2 upon undergoing any of the tests mentioned in sub-paragraph (a);
 - (c) if the recovered individual was granted a certificate under paragraph (3)(d) — for a period starting the date the individual first tested positive for SARS-CoV-2 upon undergoing any of the tests mentioned in sub-paragraph (a) that led to the assessment of the individual having the last infection and ending on the later of the following:
 - (i) the last day of the period mentioned in paragraph (3)(d);
 - (ii) the 180th day.”; and

(b) after paragraph (5), insert —

“(5A) Where paragraph (5)(a) or (b) applies, the Director or a recognised medical practitioner may, where satisfied that the recovered individual has been administered another dose of any approved vaccine (whether before, on or after 1 June 2022), grant a certificate stating the individual has a cleared status (general) for an indefinite period starting the date that other dose is administered if —

(a) in the case of paragraph (5)(a) — the other dose is administered at least 86 days after the date the last dose of the primary vaccination was administered on the recovered individual;

(b) in the case of paragraph (5)(b) — the other dose is administered at least 86 days after the date the recovered individual first tested positive for SARS-CoV-2 for that infection.”.

Amendment of regulation 7A

4. In regulation 7A —

(a) in paragraph (2)(f)(i), replace “3 months” with “6 months”;

(b) in paragraph (2)(f)(ii), replace “365 days” with “6 months”; and

(c) after paragraph (3), insert —

“(3A) Despite paragraph (2) or (3), if a certificate is granted under that paragraph in respect of an individual on or before 31 May 2022, the certificate expires on —

(a) the date that the period specified in the certificate expires; or

(b) 1 August 2022,

whichever is earlier.”.

Amendment of First Schedule

5. In the First Schedule to the principal Regulations —

(a) in item 1, in paragraphs (1) and (2), in the fourth column, replace “Indefinite after the start of the period.” with “270th day (including that day) after the day the dose is administered.”;

(b) in item 1, after paragraph (2), insert —

“

(2A) Vaccination in accordance with paragraph (1) or (2), followed by another dose of any approved vaccine, administered at least 86 days after the day the first dose is administered.	The day the second dose is administered in accordance with the second column.	Indefinite after the start of the period.
---	---	---

”;

(c) in item 2, in paragraphs (1) and (2), in the fourth column, replace “Indefinite after the start of the period.” with “270th day (including that day) after the day the dose is administered.”;

(d) in item 2, after paragraph (2), insert —

“

(2A) Vaccination in accordance with paragraph (1) or (2), followed by another dose of any approved vaccine, administered at least 86 days after the day the first dose is administered.	The day the second dose is administered in accordance with the second column.	Indefinite after the start of the period.
---	---	---

”;

(e) in item 3, in paragraphs (1) and (2), in the fourth column, replace “Indefinite after the start of the period.” with “270th day (including that day) after the day the dose is administered.”;

(f) in item 3, after paragraph (2), insert —

<p>(2A) Vaccination in accordance with paragraph (1) or (2), followed by another dose of any approved vaccine, administered at least 86 days after the day the first dose is administered.</p>	<p>The day the second dose is administered in accordance with the second column.</p>	<p>Indefinite after the start of the period.</p>
--	--	--

(g) in item 4, in paragraphs (1) and (2), in the fourth column, replace “Indefinite after the start of the period.” with “270th day (including that day) after the day the dose is administered.”;

(h) in item 4, after paragraph (2), insert —

<p>(2A) Vaccination in accordance with paragraph (1) or (2), followed by another dose of any approved vaccine, administered at least 86 days after the day the first dose is administered.</p>	<p>The day the second dose is administered in accordance with the second column.</p>	<p>Indefinite after the start of the period.</p>
--	--	--

(i) in item 4, in paragraph (5), in the second column, replace “At least 2 doses of approved vaccines, one of which is the approved vaccine opposite” with “Vaccination in accordance with paragraph (4)”;

(j) in item 5, in paragraphs (3), (4), (5) and (6), in the fourth column, replace “Indefinite after the start of the period.” with “270th day (including that day) after the day the second dose is administered.”;

(k) in item 5, after paragraph (6), insert —

“

(6A) Vaccination in accordance with paragraph (3), (4), (5) or (6), followed by another dose of any approved vaccine, administered at least 86 days after the day the second dose is administered.	The day the third dose is administered in accordance with the second column.	Indefinite after the start of the period.
--	--	---

”;

(l) in item 6, in paragraphs (3), (4), (5), (6), (7) and (8), in the fourth column, replace “Indefinite after the start of the period.” with “270th day (including that day) after the day the second dose is administered.”;

(m) in item 6, after paragraph (8), insert —

“

(8A) Vaccination in accordance with paragraph (3), (4), (5), (6), (7) or (8), followed by another dose of any approved vaccine, administered at least 86 days after the day the second dose is administered.	The day the third dose is administered in accordance with the second column.	Indefinite after the start of the period.
--	--	---

”;

(n) in item 7, in paragraphs (1) and (2), in the fourth column, replace “Indefinite after the start of the period.” with “270th day (including that day) after the day the dose is administered.”;

(o) in item 7, after paragraph (2), insert —

“

(2A) Vaccination in accordance with paragraph (1) or (2), followed by another dose of any approved vaccine, administered at least 86 days after the day the first dose is administered.	The day the second dose is administered in accordance with the second column.	Indefinite after the start of the period.
---	---	---

”;

(p) in item 8, in paragraphs (1) and (2), in the fourth column, replace “Indefinite after the start of the period.” with “270th day (including that day) after the day the dose is administered.”;

(q) in item 8, after paragraph (2), insert —

“

(2A) Vaccination in accordance with paragraph (1) or (2), followed by another dose of any approved vaccine, administered at least 86 days after the day the first dose is administered.	The day the second dose is administered in accordance with the second column.	Indefinite after the start of the period.
---	---	---

”; and

(r) after item 8, insert —

<p>9. Convidecia (CanSino Biologics COVID-19 vaccine)</p>	<p>(1) One dose of the approved vaccine opposite, administered to a Type T recovered individual at least 28 days after the recovered individual first tested positive for SARS-CoV-2.</p>	<p>14th day after the dose is administered in accordance with the second column.</p>	<p>270th day (including that day) after the day the dose is administered.</p>
	<p>(2) One dose of the approved vaccine opposite, administered to a Type S recovered individual after his or her recovery from the COVID-19 infection.</p>	<p>14th day after the dose is administered in accordance with the second column.</p>	<p>270th day (including that day) after the day the dose is administered.</p>
	<p>(3) Vaccination in accordance with paragraph (1) or (2), followed by another dose of any approved vaccine, administered at least 86 days after the day the first dose is administered.</p>	<p>The day the second dose is administered in accordance with the second column.</p>	<p>Indefinite after the start of the period.</p>
	<p>(4) One dose of the approved vaccine opposite.</p>	<p>14th day after the dose is administered.</p>	<p>270th day (including that day) after the day the dose is administered.</p>

	(5) One dose of the approved vaccine opposite, followed by a dose of another approved vaccine, administered at least 86 days after the first mentioned dose is administered.	The day the second dose is administered in accordance with the second column.	Indefinite after the start of the period.
	(6) Vaccination in accordance with paragraph (5), and where the doses are administered at a shorter interval than as specified in paragraph (5) and allowed by the Director.	The day the second dose is administered in accordance with the second column.	270th day (including that day) after the day the first dose is administered plus a period fixed by the Director, being not more than 85 days and corresponding to the actual interval between the first and second doses. „

[G.N. Nos. S 310/2021; S 324/2021; S 367/2021; S 396/2021; S 513/2021; S 542/2021; S 590/2021; S 620/2021; S 682/2021; S 768/2021; S 774/2021; S 863/2021; S 908/2021; S 991/2021; S 9/2022; S 49/2022; S 69/2022; S 91/2022; S 102/2022; S 180/2022; S 226/2022; S 317/2022; S 326/2022]

Made on 31 May 2022.

NG HOW YUE
*Permanent Secretary
(Health Development),
Ministry of Health,
Singapore.*

[AG/LEGIS/SL/137/2020/13 Vol. 4]